Rubella virus vaccine
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Rubella virus vaccine
- Accession Number
- DB10317
- Description
Rubella virus vaccine is a live attenuated virus vaccine for active immunization against rubella (German measles) that is subcutaneously administered. It is prepared from RA 27/3 strain of live attenuated rubella virus. Rubella is a common childhood disease, caused by rubella virus (togavirus).
- Type
- Biotech
- Groups
- Approved, Investigational
- Biologic Classification
- Vaccines
Attenuated - Synonyms
- Rubella virus (vaccine strain ra27/3) live antigen
- Rubella virus live antigen, A
- Rubella virus strain wistar ra 27/3 live (attenuated) antigen
- Rubella virus strain wistar ra 27/3 live antigen
- Rubella virus vaccine live (wistar ra 27-3 strain)
- Rubella virus vaccine,live
- Rubella, live attenuated
- Rubivirus rubella virus wistar ra 27/3 whole
Pharmacology
- Indication
- Not Available
- Associated Conditions
- Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Unlock Additional DataAbacavir The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Abacavir. Abatacept The risk or severity of infection can be increased when Rubella virus vaccine is combined with Abatacept. Acyclovir The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Acyclovir. Adalimumab The risk or severity of infection can be increased when Rubella virus vaccine is combined with Adalimumab. Adefovir dipivoxil The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Adefovir dipivoxil. Aldesleukin The risk or severity of infection can be increased when Rubella virus vaccine is combined with Aldesleukin. Alefacept The risk or severity of infection can be increased when Rubella virus vaccine is combined with Alefacept. Alemtuzumab The risk or severity of infection can be increased when Rubella virus vaccine is combined with Alemtuzumab. Altretamine The risk or severity of infection can be increased when Rubella virus vaccine is combined with Altretamine. Amantadine The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Amantadine. Additional Data Available- Extended DescriptionExtended Description
Extended description of the mechanism of action and particular properties of each drug interaction.
Learn more - Severity
- Evidence Level
- ActionAction
An effect category for each drug interaction. Know how this interaction affects the subject drug.
Learn more
- Food Interactions
- Not Available
Products
- International/Other Brands
- Meruvax II
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image M-M-R II Rubella virus vaccine (1000 TCID50/0.5mL) + Measles virus vaccine live attenuated (1000 TCID50/0.5mL) + Mumps virus strain B level jeryl lynn live antigen (12500 TCID50/0.5mL) Powder, for solution Subcutaneous Merck Ltd. 1979-12-31 Not applicable Canada 
M-M-R II Rubella virus vaccine (1000 [TCID_50]/0.5mL) + Measles virus vaccine live attenuated (1000 [TCID_50]/0.5mL) + Mumps virus strain B level jeryl lynn live antigen (12500 [TCID_50]/0.5mL) Injection, powder, lyophilized, for suspension Subcutaneous A-S Medication Solutions 1971-04-21 Not applicable US 
M-M-R II Rubella virus vaccine (1000 [TCID_50]/0.5mL) + Measles virus vaccine live attenuated (1000 [TCID_50]/0.5mL) + Mumps virus strain B level jeryl lynn live antigen (12500 [TCID_50]/0.5mL) Injection, powder, lyophilized, for suspension Subcutaneous Physicians Total Care, Inc. 1996-08-07 2012-06-30 US M-M-R II Rubella virus vaccine (1000 [TCID_50]/0.5mL) + Measles virus vaccine live attenuated (1000 [TCID_50]/0.5mL) + Mumps virus strain B level jeryl lynn live antigen (12500 [TCID_50]/0.5mL) Injection, powder, lyophilized, for suspension Subcutaneous Merck Sharp & Dohme Corp. 1971-04-21 Not applicable US Priorix Rubella virus vaccine (103.0 CCID50/0.5mL) + Measles virus vaccine live attenuated (103.0 CCID50/0.5mL) + Mumps virus strain B level jeryl lynn live antigen (103.7 CCID50/0.5mL) Kit; Powder, for solution Intramuscular; Subcutaneous Glaxosmithkline Inc 1998-12-04 Not applicable Canada ProQuad Rubella virus vaccine (1000 [TCID_50]/0.5mL) + Measles virus vaccine live attenuated (1000 [TCID_50]/0.5mL) + Mumps virus strain B level jeryl lynn live antigen (20000 [TCID_50]/0.5mL) + Varicella Zoster Vaccine (Live/attenuated) (9772 [PFU]/0.5mL) Injection, powder, lyophilized, for suspension Subcutaneous Merck Sharp & Dohme Corp. 2015-07-01 Not applicable US ProQuad Rubella virus vaccine (1000 [TCID_50]/0.5mL) + Measles virus vaccine live attenuated (1000 [TCID_50]/0.5mL) + Mumps virus strain B level jeryl lynn live antigen (20000 [TCID_50]/0.5mL) + Varicella Zoster Vaccine (Live/attenuated) (9772 [PFU]/0.5mL) Injection, powder, lyophilized, for suspension Subcutaneous Merck Sharp & Dohme Limited 2005-09-06 2018-08-31 US ProQuad Rubella virus vaccine (3 log10 tcid50/0.5mL) + Measles virus vaccine live attenuated (3 log10 tcid50/0.5mL) + Mumps virus strain B level jeryl lynn live antigen (4.3 log10 tcid50/0.5mL) + Varicella Zoster Vaccine (Live/attenuated) (3.99 log10 tcid50/0.5mL) Powder, for solution Subcutaneous Merck Ltd. 2014-05-09 Not applicable Canada
Categories
- ATC Codes
- J07BJ01 — Rubella, live attenuated
- Drug Categories
- Classification
- Not classified
Chemical Identifiers
- UNII
- 52202H034Z
- CAS number
- Not Available
References
- General References
- TITCK Product Information: R-VAC (rubella vaccine, live, attenuated) for subcutaneous injection [Link]
- External Links
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Prevention BCG Infection / Immune Response / Reaction - Vaccine 1 4 Completed Prevention Chickenpox / Hepatitis A / Mumps / Rubella / Rubeola 1 4 Completed Prevention Encephalitis, Japanese B / Mumps / Rubella / Rubeola 1 4 Completed Prevention Hepatitis A Virus 1 4 Completed Prevention Measles Antibody Seroconversion / Rotavirus Geometric Mean Titer (GMT) / Rotavirus Immunoglobulin A (IgA) Seropositivity / Rubella Antibody Seroconversion 1 4 Completed Prevention Mumps / Rubella / Rubeola 2 3 Active Not Recruiting Prevention Malaria Vaccines / Plasmodium Infections 1 3 Active Not Recruiting Treatment Infections, Pneumococcal 1 3 Completed Prevention Acellular Pertussis / Diphtheria / Poliomyelitis / Tetanus 1 3 Completed Prevention Acellular Pertussis / Diphtheria / Tetanus 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, powder, lyophilized, for suspension Subcutaneous Injection, powder, for suspension Intramuscular; Subcutaneous 1000 CCID50/0.5mL Injection, powder, lyophilized, for solution Intramuscular; Subcutaneous 1000 TCID Injection, powder, for solution Intramuscular; Subcutaneous 103 CCID50/0.5mL Injection, powder, for solution Subcutaneous 103 CCID50/0.5mL Kit; powder, for solution Intramuscular; Subcutaneous Injection, powder, lyophilized, for solution Intramuscular; Subcutaneous 10 CCID Injection, powder, for solution Subcutaneous 10 CCID Injection, powder, lyophilized, for solution Subcutaneous 10 CCID Injection, powder, for suspension Intramuscular; Subcutaneous 1000 [TCID_50]/0.5mL Injection, powder, lyophilized, for suspension Intramuscular; Subcutaneous 1000 [TCID_50]/0.5mL Powder, for solution Subcutaneous Injection, powder, lyophilized, for suspension Intramuscular; Subcutaneous 3 log10/0.5ml Injection Subcutaneous 0.5 ml Injection Subcutaneous 1000 CCID50/0.5mL - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created on December 01, 2015 13:03 / Updated on September 03, 2020 14:54
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
![]({"CS-Molecular-Health-1.jpg":"/assets/ads/CS-Molecular-Health-1-19e76f023997d5ac198da2cb9976457f7b9ba733f0ea8a780fe21191c759e8fa.jpg","Drug-Dev-2.jpg":"/assets/ads/Drug-Dev-2-7c3039d93245f493c23278efbf759e4f933848a676262d579087d5cc516af179.jpg","Drug-Search-3.jpg":"/assets/ads/Drug-Search-3-7346c33d2133f62b46cbfbbe2b666e78f955c6847e242692c6081fec37c4d10d.jpg","PM-3.jpg":"/assets/ads/PM-3-13494ac4c996d71619127a11f685681418d4280832dec162c0b2c9c8bc2eda50.jpg","OD-Webinar-1.jpg":"/assets/ads/OD-Webinar-1-f9357f6d57fef5e411aa1c0439ef46c86d9151214434659d096eeed6407b799b.jpg","DDI-3.jpg":"/assets/ads/DDI-3-12808cf864d540ad43757b10b08fc52ae93e793b0c6e81345555187b2840ad09.jpg","EMR-2.jpg":"/assets/ads/EMR-2-adacf8de3f42cb06d6676d06fce611c29781db6ad30776cd18b72a7d8e69f0c8.jpg","Covid.jpg":"/assets/ads/Covid-eed8f17668b0308db62ce3c656f5e2f562376e9185ae08dda5ce6ed9ab0bbd1f.jpg","CS-Molecular-Health-2.jpg":"/assets/ads/CS-Molecular-Health-2-22f41f94b3f87e44a1dcaa8f6c03dc411ab69558efd4f3148ff9bb6adaa956dc.jpg","PM-5.jpg":"/assets/ads/PM-5-d0dc031e0fa0d0097d912eff07b7e80b27b867264dd5b055e379a57bfa2a8723.jpg","DDI-4.jpg":"/assets/ads/DDI-4-313b9c374b937fd78bb2ade652b9b030abb9e6cb90efd35833f793e384e8185b.jpg","Discover-1.jpg":"/assets/ads/Discover-1-b48ae6a3872eeb442f4c22a9a1d867428c83a917ec78a8c3ff4e02f84c5d4fef.jpg","Discover-2.jpg":"/assets/ads/Discover-2-6e7759998ee0fdc234cd84eea962f2480f0c7dafadabd785924918420decb102.jpg","Repurpose-1.jpg":"/assets/ads/Repurpose-1-265fbec40f0eac18d51d3ec4f558c10cb623d834ea75e0296259e458b72ee6d4.jpg","Repurpose-2.jpg":"/assets/ads/Repurpose-2-d12bd1d18b92d36eab60e71e6fd59acf04ef60a53783570e11eef397a0e0f4f5.jpg","PM-6.jpg":"/assets/ads/PM-6-3ae66e41f7ae1e851a0910be89141cf2533509b46df6379464efc885d5ee2f07.jpg","Drug-Search-4.jpg":"/assets/ads/Drug-Search-4-2a9102bd41f16e8c40c9d8044d1dcb6f206ff80107cc269aa83d02ea683bc829.jpg","DDI-5.jpg":"/assets/ads/DDI-5-fa1c287946f4044094c723161577cb5ac631f9cd1217446e510dc79ace6cb94e.jpg","TH-1.jpg":"/assets/ads/TH-1-55a9077bb39e8c38a68c67b555b8091d21a9d41b1c21c7daed3fe53e6f9f3c97.jpg","TH-2.jpg":"/assets/ads/TH-2-1d488747fa4af00ab970a48dba0b228b054d166aa22c1760a310e2b72dd22589.jpg"})
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates